Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
2024
2024
“Stealth”
2020
2020
Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health Born from our collective experience as founders, we set out to build the fund we wanted to raise from... Thesis: Life Sciences is experiencing rapid innovation with the rise of new generation of companies known as “TechBio” (Merging technology & biology), a change we believe is leading to some of the most impactful solutions in decades. Our passion is to help build transformative companies ahead of this revolution to significantly impact the quality & effectiveness of patient care. We aim to partner with passionate, accomplished founders who possess unique insights to solve some of the world’s most daring problems facing us in Life Sciences. Team: Our entire team is built of Life Science Founders with experience in raising capital, scaling teams, running labs, partnering with Pharma, & the many fires that consist of operating an early stage company. SAB: Composed of Bioengineering PhDs turned Founders, our Scientific Advisory Board provides deep technical expertise & fluency across a wide variety of Life Science sub-domains from platforms for “Novel Applications” (Therapeutics/Diagnostics) to “Bio-Economy Infrastructure” (Tools/Services/Manufacturing). Let’s talk science! Support: Helping our founders is our utmost priority. To tackle the many challenges ahead, we’ve curated a full platform of resources to help with customer introductions, fundraising, & team building, amongst others. In addition, dedicated to supporting our portfolio is our extensive network of industry executives spanning Top 25 Pharma, major health systems, & large Payors. Limited Partners: Anchored by leading strategic LPs making up some of the best venture capital firms in the world, veteran founders, & industry experts. Alix is here to fill the void for early stage Life Science capital.
2020
2020
Uniting the Life Science ecosystem in #PatientImpact — Spotlighting leaders in Academia, Startups, Pharma, & VC — By Alix Ventures
2021
"Enhancing Therapeutic Potency Through Conditional Activation" Co-Investors: Viking Global, Foresite Capital, Perceptive Advisors, Venrock, First Round, OMX, Lifeforce, amongst others
2022
"Enabling Logic Gated Gene Therapy" Co-Investors: FPV, Playground, Redmile, Eli Lilly, amongst others
2020
2020
"Enabling Full Stack DNA Writing" Co-Investors: a16z, 8VC, KdT, amongst others
2023
2023
“Enabling Ultra-High Throughput Chemical Synthesis” Co-Investors: Stealth
2022
2022
"Enabling Genomic Insights for Under Represented Populations" Co-Investors: F-Prime, Digitalis, AME Cloud, amongst others
2021
2021
"Enabling Ultra-High Throughput Single Cell Screening & Manipulation" Co-Investors: Stealth
2023
2023
"Enhancing Therapeutic Efficacy By Targeting Tumor Acidity" Co-Investors: Stealth